MUNICH, Germany, May 5 /PRNewswire/ -- Ingenium Pharmaceuticals AG announced today the addition of Georges Haas, Ph.D., to its Supervisory Board. Dr. Haas, who retired as Worldwide Head of Pharmaceutical Research and Preclinical Development at Ciba-Geigy in 1997, has had an extensive 27-year career in pharmaceutical development. Dr. Haas replaces Kate Bingham, General Partner of Schroder Ventures Life Sciences, who joined Ingenium's Supervisory Board in 2000 and stepped down at the end of 2003.
"Georges is a respected statesman in the pharmaceutical industry and has an outstanding track record in drug discovery and development, as well as in bringing innovative therapeutics to patients," stated Michael C. Nehls, M.D., Ph.D., CEO of Ingenium. "We consider ourselves fortunate to have Georges' expertise and support on our Supervisory Board as Ingenium continues to develop its own portfolio of novel biological discoveries."
"Ingenium would also like to thank Kate for her valuable contributions and guidance, which accelerated Ingenium's corporate development and maturity," Dr. Nehls added.
Dr. Haas had a distinguished 27-year career with Ciba-Geigy Pharmaceuticals. During his tenure, he developed pioneering strategies to speed the drug discovery and development process. In his final position as Head of Worldwide Pharmaceutical and Preclinical Development, he was responsible for over 2000 employees in Europe, Japan and the United States. In addition to serving as author on a number of publications, he holds numerous patents in the field of pharmaceuticals. Currently, Dr. Haas works with a select group of venture capital backed companies. Dr. Haas received his doctorate in chemistry from the Federal Institute of Technology (ETH), Zurich, and completed his postdoctoral training at Cornell University. He also completed management training at the Harvard Business School.
The basis of Ingenium's business is its knowledge and expertise in generating the biological information critical to the discovery, validation and development of therapeutics. Ingenium's drug discovery technologies combine functional genetics in the rodent model system with proprietary, therapeutic goal-oriented biological screens and advanced biological pathway analysis. From the breadth of knowledge generated by the company's Deductive Genomics(R) technology, Ingenium is currently advancing a portfolio of validated therapeutic concepts in the areas of inflammation, obesity/diabetes, and neurobiology. The company's INGENOtyping(TM) platform offers the most rapid access to innovative rat and mouse models for drug discovery and development and drug target validation. Ingenium has research partnership agreements with Elan Corporation, Bayer AG, F. Hoffmann-La Roche Ltd., Gruenenthal, Molecular Engines Laboratories, Sequenom Inc., Oxagen Limited, and Wyeth, in addition to numerous international academic collaborations.
Ingenium and Deductive Genomics are registered U.S. trademarks.
For more information contact:
Gretchen L.P. Schweitzer
Vice President Corporate Communications
Ingenium Pharmaceuticals AG
Ingenium Pharmaceuticals AG